Michael Ryskin, an analyst from Bank of America Securities, maintained the Buy rating on Thermo Fisher. The associated price target remains the same with $650.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ryskin has given his Buy rating due to a combination of factors including Thermo Fisher’s strategic acquisition of Clario. This acquisition is expected to be accretive to Thermo Fisher’s earnings, adding 45 cents per share in the first year alone. Clario, a clinical end-point data vendor, is seen as a strong strategic fit that will enhance Thermo Fisher’s existing clinical trial offerings, particularly through its integration with PPD.
Additionally, the acquisition is anticipated to bolster Thermo Fisher’s position in the clinical development value chain by combining physical trial operations with digital insights, thereby improving data quality and speed. The deal is projected to generate significant revenue synergies and operating margin improvements over time, reinforcing Thermo Fisher’s ability to effectively deploy capital in accretive mergers and acquisitions. These factors collectively support Ryskin’s positive outlook and Buy rating for Thermo Fisher’s stock.
Ryskin covers the Healthcare sector, focusing on stocks such as Agilent, Icon, and Bruker. According to TipRanks, Ryskin has an average return of 4.3% and a 59.09% success rate on recommended stocks.